On the Need to Distinguish between Insulin-Normal and Insulin-Resistant Patients in Testosterone Therapy

Area of Science:

• Endocrinology and Metabolism
• Systems Biology
• Biochemistry

Background:

• Male hypogonadism is characterized by low testosterone and can present with either insulin sensitivity (IS) or insulin resistance (IR).
• These distinct metabolic states lead to varied clinical complications and biochemical pathway alterations.
• Understanding the interplay between testosterone and insulin is crucial for managing hypogonadism.

Purpose of the Study:

• To compare metabonomic differences in hypogonadism between IS and IR patients before and after testosterone therapy (TRT).
• To investigate the synergistic or antagonistic relationship between testosterone and insulin.
• To elucidate the metabolic adaptations and outcomes of TRT in different hypogonadal states.

Main Methods:

• Comparative analysis of metabonomic profiles in hypogonadal patients with IS and IR.
• Assessment of metabolic changes pre- and post-TRT.
• Review of literature focusing on biochemical pathways, including the Krebs cycle, gluconeogenesis, and fatty acid oxidation.

Main Results:

• IS hypogonadism primarily utilizes glucose, while IR shifts towards gluconeogenesis and lipogenesis.
• TRT increases glucose utilization more significantly in IS than in IR, indicating a metabolic switch to lipid oxidation in IR.
• Both conditions result in elevated lactate and acetyl-CoA, with higher levels in IR, leading to ketonuria.

Conclusions:

• TRT is more effective in restoring metabolic pathways in IS hypogonadism compared to IR.
• Hypogonadism may progress from an IS to an IR state over time, with limited reactivation of insulin-related metabolisms post-TRT in IR.
• Supplementation with specific metabolites alongside TRT may enhance the restoration of physiological metabolism in both IS and IR patients.